JNJ - Johnson & Johnson
| Previous close | 128.64 |
| Open | 128.61 |
| Bid | 128.74 x 800 |
| Ask | 128.75 x 900 |
| Day's range | 128.16 - 129.45 |
| 52-week range | 121.00 - 148.99 |
| Volume | 3,318,823 |
| Avg. volume | 7,190,596 |
| Market cap | 342.091B |
| Beta (3Y monthly) | 0.76 |
| PE ratio (TTM) | 21.40 |
| EPS (TTM) | 6.02 |
| Earnings date | 15 Oct 2019 |
| Forward dividend & yield | 3.80 (2.95%) |
| Ex-dividend date | 2019-08-26 |
| 1y target est | 149.28 |
- Zacks•3 hours ago
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
- Zacks•5 hours ago
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
- Motley Fool•8 hours ago
3 of the Most Rock-Solid Dividend Stocks in the World
These income stocks look incredibly secure for a long time to come.
- Motley Fool•yesterday
The 10 Biggest Blue Chip Stocks
These top-quality stocks lead their industries, and they've been good to investors over the long run.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
- Zacks•yesterday
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
- Zacks•yesterday
Stocks Slip This Week on Earnings, Fed Uncertainties
Stocks Slip This Week on Earnings, Fed Uncertainties
- Motley Fool•yesterday
Is Johnson & Johnson a Buy?
The pros and the cons for this giant healthcare stock.
- Business Wire•3 days ago
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
- CNBC•4 days ago
Judge denies J&J's request to transfer 2,400 talc lawsuits to federal court
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.
- Zacks•4 days ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
- Zacks•4 days ago
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Zacks•4 days ago
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
- Zacks•5 days ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- Zacks•5 days ago
Top Stock Reports for Johnson & Johnson, NextEra & Deere
Top Stock Reports for Johnson & Johnson, NextEra & Deere
- Market Realist•5 days ago
Litigation Looms in the Wake of JNJ’s Solid Q2 Earnings
Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.
- Motley Fool•5 days ago
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
- Zacks•6 days ago
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
- Yahoo Finance•7 days ago
Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
- Yahoo Finance•7 days ago
Stocks slip slightly amid trade remarks, earnings season
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
Motley Fool•7 days agoJohnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript
JNJ earnings call for the period ending June 30, 2019.
- Bloomberg•7 days ago
J&J Ups Sales Forecast as Cancer Drugs Drive Growth
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- CNBC•7 days ago
J&J vows to defend itself in talc, opioid lawsuits
Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.
- Zacks•7 days ago
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
